Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
- Market Cap ₹ 28,770 Cr.
- Current Price ₹ 1,020
- High / Low ₹ 1,098 / 581
- Stock P/E 232
- Book Value ₹ 331
- Dividend Yield 0.25 %
- ROCE 14.2 %
- ROE 5.44 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.08 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.44% over past five years.
- Company has a low return on equity of 10.6% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 12.8% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4,021 | 5,012 | 6,005 | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,990 | 12,124 | |
3,306 | 3,997 | 4,914 | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 10,712 | 10,828 | |
Operating Profit | 714 | 1,015 | 1,091 | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 2,278 | 1,296 |
OPM % | 18% | 20% | 18% | 18% | 19% | 22% | 18% | 16% | 16% | 19% | 19% | 18% | 11% |
18 | 11 | 11 | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -449 | -990 | |
Interest | 147 | 160 | 189 | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 350 | 477 |
Depreciation | 98 | 127 | 217 | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 611 | 577 |
Profit before tax | 488 | 739 | 697 | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 868 | -748 |
Tax % | 5% | 15% | 22% | 61% | 29% | 26% | 28% | 29% | 29% | 30% | 31% | 57% | |
464 | 628 | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -622 | |
EPS in Rs | 17.02 | 22.89 | 19.99 | 7.72 | 26.33 | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -25.22 |
Dividend Payout % | 3% | 0% | 0% | 26% | 8% | 5% | 7% | 6% | 9% | 7% | 7% | 24% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 7% |
3 Years: | 7% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | -2% |
5 Years: | -9% |
3 Years: | -13% |
TTM: | -85% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 12% |
3 Years: | 19% |
1 Year: | 69% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 12% |
3 Years: | 11% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 27 | 27 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
Reserves | 2,375 | 2,736 | 2,956 | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 9,299 |
2,244 | 2,765 | 3,267 | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,627 | 5,182 | |
1,087 | 1,466 | 2,176 | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,228 | 5,498 | |
Total Liabilities | 5,733 | 6,994 | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 20,006 |
2,223 | 2,822 | 3,091 | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 6,202 | 5,531 | |
CWIP | 263 | 6 | 5 | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,251 | 1,221 |
Investments | 0 | 0 | 0 | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 45 |
3,248 | 4,166 | 5,331 | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 11,830 | 13,210 | |
Total Assets | 5,733 | 6,994 | 8,427 | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,329 | 20,006 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
804 | 648 | 854 | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | |
-318 | -558 | -566 | -712 | -950 | -1,001 | -1,003 | -883 | -774 | -662 | -316 | -515 | |
-361 | 195 | -98 | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | -77 | |
Net Cash Flow | 125 | 285 | 190 | -31 | 93 | 199 | 177 | -297 | 174 | 28 | 272 | 32 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 113 | 119 | 131 | 140 | 120 | 97 | 94 | 81 | 83 | 86 | 92 | 115 |
Inventory Days | 223 | 194 | 191 | 247 | 249 | 299 | 244 | 244 | 211 | 230 | 208 | 240 |
Days Payable | 220 | 239 | 279 | 379 | 308 | 243 | 225 | 241 | 210 | 226 | 190 | 192 |
Cash Conversion Cycle | 116 | 75 | 43 | 8 | 61 | 152 | 113 | 85 | 84 | 90 | 110 | 162 |
Working Capital Days | 150 | 94 | 83 | 66 | 89 | 133 | 111 | 76 | 69 | 96 | 100 | 111 |
ROCE % | 14% | 18% | 15% | 16% | 19% | 21% | 15% | 15% | 14% | 15% | 16% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1h - Glenmark Pharmaceuticals Limited will host an 'Investor Day 2024' from 16:30 to 18:30 IST (07:00 to 09:00 EDT) on Thursday, 30 May 2024, in Mumbai. …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10h - Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Opthalmic Solution, 0.2% / 0.5%
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Details of Earnings Call slated for Monday, May 27, 2024 at 08:30 a.m. to 09:30 a.m. (IST) for your information and record.
- Closure of Trading Window 14 May
- Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2024 And Recommending Dividend, If Any, On Equity Shares For The Year Ended March 31, 2024 14 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Dec 2016TranscriptNotesPPT
-
Jul 2016TranscriptNotesPPT
-
Jan 2016TranscriptNotesPPT
Leadership[1]
<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>